Revised Ph. Eur. Monographs on Excipients due to ICH Q3D
Recommendation

18-20 November 2026
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Several revised Ph. Eur. Monographs on excipients commonly used in semi-solid formulations (e.g. oils, fats, waxes, emulsifiers) have been proposed in Pharmeuropa 30.2. Deadline for comments is June 30, 2018.
In line with the Ph. Eur. implementation strategy for the ICH Q3D guideline on elemental impurities, the test on Nickel is proposed for deletion as the relevant elemental impurities are considered to originate from the production process. A change to this effect has been introduced in the Production section of the general Ph. Eur. monograph “Substances for pharmaceutical use” (with Ph. Eur. supplement 9.3), as only the manufacturer of a substance for pharmaceutical use knows which elemental impurities may be potentially introduced as catalysts and reagents, and whose levels would therefore need to be controlled.
This affects the following Ph. Eur. Monographs:
- Hard fat
- Hard fat with additives
- Arachis oil, hydrogenated
- Castor oil, hydrogenated
- Cottonseed oil, hydrogenated
- Glycerol dibehenate
- Glycerol distearate
- Glycerol monostearate 40-55
- Macrogol 15 hydroxystearate
- Macrogol 30 dipolyhydroxystearate
- Palmitic acid
- Stearic acid
- Soya-bean oil, hydrogenated
- Squalane
- Triglycerides, medium-chain (additional removal of the tests for Chromium, Copper, Lead, Tin)
Furthermore, a draft for a new monograph on Cocoa butter has been published for comment in the same issue of Pharmeuropa.
For more information plese see Pharmeuropa Online.
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus


